People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BioAegis Therapeutics, Inc. | — | Biotechnology | Series B | $42.4M | $457.8M | 2018 |
Mark DiNubile at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark DiNubile on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Susan Levinson | 1 | 2 |
| Valerie Ceva | 1 | 2 |
| Thomas Stossel | 1 | 2 |
| Steven L. Cordovano | 1 | 1 |
| Steve Cordovano | 1 | 1 |
| Steven Cordovano | 1 | 1 |
| Susan L. Levinson | 1 | 1 |
| John Stossel | 1 | 1 |
| Valerie L. Ceva | 1 | 1 |
| Thomas L. Stossel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.